Anyone that thinks small bio-techs like CYCC are effected by earnings prior to bringing any of their drugs to the market should be shot (CYCC has a marketed product but it only covers some of the expenses. still a huge plus, 90% of the companies out there in the same stage have absolutely no way of getting money other than selling shares or loans). Cancer drugs take years and years of development, it is expected for CYCC to keep losing money until their drug is approved/partnership or a buyout occurs. If Sep is approved for just AML only (not the other diseases) CYCC will be worth at least 500 million, or 20 dollars a share with current share structure (which is likely to change by then, CYCC has less than 25 million shares outstanding compared to 100 million + with most of the other companies in the same stage)

Short term is decent here, there is a good 50% gain, long term (1-2 years) is insane, definitely worth putting some in an IRA account.